- Business
- Company
- Contact
- Disclaimer
- Login/Online services
- Products
- Research
- Sitemap
- Technology
- Brochures
- ConferenceRepresentation
- Developing Countries
- Formulaire_news
- News
- 454 Ultra-Deep-Sequencing and the DeepChek™-HIV system
- ABL and Evivar Medical enter into Agreements to form a global strategic partnership and IP cross-licensing for disease management and personalized healthcare of Hepatitis B and HIV infections
- ABL Announces the Strengthening of Its Patent Estate: Notice of Allowance in Canada, Issuance of a Patent in India, and Issuance of Reexamination Certificates in the United States after Several Patent Reexaminations
- ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL’s TherapyEdge®-ViroScore® Platform
- ABL is partnering to the European Network TINN2
- ABL is pleased to report the Canadian Patent Office has been issued patent N° 2326579 and has been granted for 20 years from the filing date, April 1, 1999.
- ABL Licensed CRP-Santé COMET Subtyping Tool
- ABL, SA :: Solutions for HIV Disease Management
- Advanced Biological Laboratories (ABL) and PharmAccess Foundation
- Agreement with CIDRZ
- AREVIR 2011
- Barry et al. patent 6,081,786 et patent 6,188,988
- BioHealth: newsletter 1
- Biohealthcluster / ABL-DeepChek™
- Centro de Genomas®
- EASL 2011 in Berlin
- European Workshop on HIV & Hepatitis congress
- FibroMeters : the most reliable tests of liver fibrosis.
- International Workshop on HIV&HEPATITIS VIRUS
- Luciano et al. patent 6,063,028 et patent 6,317,731
- Patent License Agreement With Viralliance Inc.
- Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705
- South African Patent
- Successful Launch of the TherapyEdge® Integration Engine
- TALKING HEADS: A service that fills the follow-up gap
- The United States Patent & Trademark Office (USPTO)
- TherapyEdge® & ViroScore® at the GeSIDA congress
- TherapyEdge® (ABL group) and TCELS
- TherapyEdge® ABL SA and BioLiveScale SA
- TherapyEdge® Chronic Care Management
- TherapyEdge® Launches the HIV eRegister for Windows
- TherapyEdge® Liver Diseases
- TherapyEdge®, ABL and MSH
- Trade News
- News-Developing countries
- NewsWorld
- OthersBrochures
- OurPatent
- Patents/Licensing
- ABL and Evivar Medical enter into Agreements to form a global strategic partnership and IP cross-licensing for disease management and personalized healthcare of Hepatitis B and HIV infections
- ABL Announces the Strengthening of Its Patent Estate: Notice of Allowance in Canada, Issuance of a Patent in India, and Issuance of Reexamination Certificates in the United States after Several Patent Reexaminations
- ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL’s TherapyEdge®-ViroScore® Platform
- ABL is pleased to report the Canadian Patent Office has been issued patent N° 2326579 and has been granted for 20 years from the filing date, April 1, 1999.
- ABL Licensed CRP-Santé COMET Subtyping Tool
- Barry et al. patent 6,081,786 et patent 6,188,988
- Centro de Genomas®
- Luciano et al. patent 6,063,028 et patent 6,317,731
- Patent License Agreement With Viralliance Inc.
- Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705
- South African Patent
- The United States Patent & Trademark Office (USPTO)
- ProductHome
- Products
- Publications
- A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
- Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients candidate to CCR5 antagonist treatment.
- Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.
- Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome
- Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients.
- Detection of low frequency drug resistant mutations in antiretroviral-treated HIV-1C infections
- Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection.
- Direct comparison with 454 pyrosequencing validates V3-loop based genotyping in patients eligible for Maraviroc initiation.
- Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected Using Ultra-Deep Pyrosequencing.
- Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies.
- Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model.
- HIV Drug Resistance Surveillance Using Pooled Pyrosequencing.
- HIV Sequence Variation Associated With env Antisense Adoptive T-cell Therapy in the hNSG Mouse Model.
- HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
- HIV-1 Dual/Mixed Tropic Isolates Show Different Genetic and Phenotypic Characteristics and Response to Maraviroc In Vitro.
- HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
- Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.
- Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
- Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and ”Deep” Sequencing to Plasma RNA and Proviral DNA
- In vitro selection of clinically relevant bevirimat resistance mutations revealed by “deep” sequencing of serially passaged, quasispecies-containing recombinant HIV-1.
- In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing.
- Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
- Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution.
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment-Naïve Populations and Associate with Reduced Treatment Efficacy
- Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
- Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
- Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response
- Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
- Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China
- Prevalence of Low Abundance Drug Resistant Variants by Ultra Deep Sequencing in Chronically HIV-infected Antiretroviral (ARV) Naïve Patients and the Impact on VirologicOutcomes
- Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
- Tenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations during Failure with Persistent Viremia as Detected by Ultradeep Pyrosequencing.
- The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time-An Ultra-Deep Approach.
- Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing.
- Services
- Western World
- 454 Ultra-Deep-Sequencing and the DeepChek™-HIV system
- ABL is partnering to the European Network TINN2
- AREVIR 2011
- BioHealth: newsletter 1
- Biohealthcluster / ABL-DeepChek™
- EASL 2011 in Berlin
- European Workshop on HIV & Hepatitis congress
- FibroMeters : the most reliable tests of liver fibrosis.
- International Workshop on HIV&HEPATITIS VIRUS
- TALKING HEADS: A service that fills the follow-up gap
- TherapyEdge® & ViroScore® at the GeSIDA congress
- TherapyEdge® ABL SA and BioLiveScale SA
- TherapyEdge® Chronic Care Management
- TherapyEdge® Launches the HIV eRegister for Windows
- TherapyEdge® Liver Diseases
- Trade News